Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium-68 DOTA-SIGLEC-9
- Development stage
- Unknown
- Lead developer
- Turku University Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Gallium-68 DOTA-SIGLEC-9 is an investigational radiopharmaceutical PET tracer developed by Turku University Hospital for the non-invasive imaging of inflammation. The agent comprises a peptide sequence derived from the Sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein, which is a natural ligand for Vascular Adhesion Protein-1 (VAP-1), also known as Amine oxidase copper containing 3 (AOC3). VAP-1 is an endothelial cell surface enzyme that mediates leukocyte recruitment and is significantly upregulated in inflamed tissues but absent from healthy vasculature. By chelating the positron-emitting isotope gallium-68 via a DOTA linker to the Siglec-9 peptide, the tracer enables high-contrast PET imaging of active inflammatory sites. It is currently being evaluated in clinical trials for the assessment of rheumatoid arthritis, various forms of vasculitis, and pulmonary sarcoidosis to aid in diagnosis and monitoring of disease activity.
- Other names
- Gallium-68 DOTA-Siglec-9 peptideGallium68 DOTA-Siglec-9 peptideGallium 68 DOTA-Siglec-9 peptide68Ga-DOTA-Siglec-9
02
Targets
AOC3 (Amine oxidase copper-containing 3)
Beyond the preview
Go deeper on gallium-68 DOTA-SIGLEC-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium-68 DOTA-SIGLEC-9.